Genetic Changes of S Gene during Co-inoculation of Two Infectious Bronchitis Virus Vaccines in SPF Chicks
Sara M. Ameen¹*, Abdullah Selim¹, Mohamed Tarek¹, Ali Zanaty¹, Mohammed AboElKhair² and AbdelHamid H. Bazid²

¹Reference Laboratory for Veterinary Quality Control on Poultry Production, Animal Health Research Institute, Agricultural Research Centre, PO Box 246, Dokki, Giza, 12618, Egypt
²Department of Virology, Faculty of Veterinary Medicine, University of Sadat City, Sadat 32897, Egypt
*Corresponding Author: Sara M. Ameen, E-Mail: sara_mahmod24@yahoo.com

ABSTRACT
Despite widespread immunizations, infectious bronchitis (IB) remains a significant issue in the Egyptian poultry industry. Multiple IBV genotypes, GI-1, GI-13, GI-16, and GI-23 have been continually circulating among chicken flocks in Egypt, inducing a substantial economic loss to the poultry sector. In addition, live attenuated vaccines representing classical and variant strains can control IBV in Egypt, mainly H120 and 793B. The H120 vaccine is widely spread and offers inadequate protection against heterotypic IBVs in the field. Therefore, a homologous live-attenuated VAR2 vaccine was developed from the Egyptian variant-2 strain Eg/1212B/2012.IB. Variant II vaccine protects against the homologous IBV challenge under experimental and field circumstances. In this study, an experimental trial was performed to simulate field practices such as heterologous vaccination of day-old specific pathogen-free chicks with IBV H120 vaccine (representing GI-1) and IB Var 2 vaccine (representing GI-23). The current study aimed to determine the existence of nucleotide and amino acid variations within the S gene in isolated viruses following ten passages in the same bird. The deduced amino acid sequence of the S gene indicated viruses isolated from the 6th and 10th passages were identical and shared (96 %) and (83 %) identities with the IB variant II vaccine and H120, respectively. However, amino acid substitutions were observed at 26 positions in the N terminal domain (S1) and S2 is conserved compared to IB Var 2 vaccine. Most amino acid modifications occurred in the receptor binding domain (RBD) of the S1 gene. HVR2 has seven amino acid changes compared to the IB Var II vaccine. Isolates of P6 and P10 lacked IBV glycosylation site at position 139 which was detected in IBV/EG/1212B/2012 as well as IB variant II vaccine. The study also revealed no evidence of recombination between the two used live vaccines.

Keywords: Glycosylation site, IBV, Live attenuated vaccine, Receptor binding domain, Spike protein.

INTRODUCTION
Infectious bronchitis (IB) disease is a severe, extremely infectious chicken viral disease, with all chicken ages being susceptible. There are three primary clinical manifestations of IB; reproductive, renal, as well as respiratory, with morbidity rates reaching one hundred percent. Nevertheless, the mortality depends on the existence of secondary infection, management, immune status, flock age, and environmental factors (Ganapathy, 2009). Based on strain virulence, the death rate among young chicks ranges from 25 to 30 percent but may surpass 80 percent (Jackwood and De Wit, 2013). It causes a substantial economic loss in the global poultry sector (Cook et al., 2012; Jackwood, 2012). IB etiological agent is infectious bronchitis virus (IBV), a gammacoronavirus member of the Coronaviridae family. The viral genome is a single-stranded, positive-sense RNA of an approximate length of 27.6 Kb (Masters and Perlman, 2013) containing 13 open reading frames (ORFs) in the sequence 5′-UTR-1a-1b-S-3a-3b-E-M-4b-4c-5a-5b-N-6b-UTR-Poly(A) tail-3′ (Payne, 2017). The three ’ one-third of the viral genome codes for four structural proteins, namely; nucleocapsid (N), spike (S), membrane (M) and
envelope (E) proteins, as well as multiple non-structural proteins (Masters and Perlman, 2013).

Additionally, spike protein presents as trimers on the virion’s surface and includes a conformation-dependent epitope (Cavanagh, 1995). The S protein is translated as a single polypeptide before being cleaved subsequently via host proteases to develop two subunits (globular head domain as well as N-terminal) as well as S2 (stalk domain as well as C-terminal) subunits that mediate viral entry as well as membrane fusion (Bosch et al., 2003; Belouzard et al., 2012).

The S1 subunit is a highly variable subunit that contains the major neutralizing epitopes (Moore et al., 1997; Wickramasinghe et al., 2011) and the receptor binding domain (RBD) crucial for tissue tropism as well as a viral attachment (Belouzard et al., 2012). To elude the host's immune response, these epitopes may change fast, especially inside the hypervariable regions (HVRs) of the S1 gene (Belouzard et al., 2012). The spikes of coronaviruses are heavily adorned with glycans on the residues of asparagine (N) (N-glycosylation, consensus sequence N-x- S/T) and are consistent among various genotypes (Shang et al., 2018; Zheng et al., 2018). The spike’s glycosylation in human coronaviruses has been shown to be a protein folding determinant (Tortorici et al., 2019; Walls et al., 2019); receptor interactions (Han et al., 2007) and the masking of neutralizing epitopes on the spike, hence impacting the immune system of the host (Zhou et al., 2010).

Three HVRs are present among the amino acids (38–67), (91–141) and (274–387) the S1 subunit (Cavanagh et al., 1988; Moore et al., 1997). HVR2 and HVR1 include sequences linked with specific IBV serotypes (Binns et al., 1986; Kusters et al., 1989) as well as serotype-specific neutralizing epitopes (Cavanagh et al., 1988; Koch et al., 1990; Kant et al., 1992). Virus characterization only depends on the HVR-III or HVR I-II regions' sequence. However, the S1 gene sequences, including three HVRs, revealed more accurate results for IBV genotyping (Mockett et al., 1984; Cavanagh et al., 1992). Many different IBV serotypes and genotypes are continually reported worldwide (Bijlenga et al., 2004; Cavanagh, 2007; Jackwood, 2012).

Mutations such as recombination, substitutions, deletions, as well as and insertions among various strains regularly take place in nature (Adzhar et al., 1997; Jackwood, 2012; Hewson et al., 2014), resulting in novel variant virus emergence (Cavanagh, 2007; Jackwood, 2012; Abolnik, 2015). Classical and mutant IBV strains co-circulate in Egypt, generating periodic disease outbreaks (Zanaty et al., 2016a; Zanaty et al., 2016b). The most prevalent lineage circulating in Egyptian poultry flocks until now is GI-23 lineage (Ghetas et al., 2016; Moharam et al., 2020). Live-attenuated vaccines have effectively contributed to controlling IB in the field (Cook et al., 1999; De Wit et al., 2011). However, live-attenuated IBV vaccines may generate variant IBV strains via recombination and/or mutations (Toro et al., 2012; Abozeid et al., 2017). Live-attenuated vaccines are primarily used to immunize broiler chickens, future prime layers, and breeder flocks (Schijns et al., 2008; Abozeid and Naguib, 2020). In Egypt, IBV infection in broilers is characterized by respiratory distress such as gasping, coughing, sneezing, or tracheal rales. Live-attenuated classical and variant vaccine strains, primarily 793B and H120 are utilized to control IB in Egypt. These vaccinations offer excellent protection against most variant viruses. However, they offer inadequate protection against certain variant field viruses of the GI-23 lineage (Sultan et al., 2019).

Lately, a homologous live-attenuated VAR2 vaccine has been generated from the Egyptian variant-2 strain Eg/1212B/2012 (GenBank accession number JQ839287). It has been used widely in Egyptian poultry farms to control IB (Ali et al., 2018). The VAR2 vaccine has experimentally offered protection against homologous IBV challenge (Ali et al., 2018).

In this study, it was reported that the genomic variations occurring in S gene following 10 passages of simultaneous in vivo inoculation of Classic and Variant II vaccines in the same chicken intermittently obtained tissues, as well as swabs, had been subjected to IBV RT-PCR that targets the N gene (Meir et al., 2010). IB VAR2 vaccine, reisolated virus of passage six and passage ten were sequenced and analyzed for amino acid alterations as well as single nucleotide polymorphisms (SNPs).

**MATERIALS AND METHODS**

**Vaccines**

IB VAR2 and H120 are two live attenuated IBV vaccines commercially available in the market and were used in the study. All immunizations were administered intranasally at the dosage advised by the manufacturer’s instructions.

**Experimental Design**

Thirty specific pathogen-free (SPF) chicks were required for ten passages of the two live attenuated vaccines (IB H120 and IB VAR2) in the same bird, three chicks for every passage. SPF chicks were obtained from Kom-Osheim SPF Project,
Fayoum, Egypt and placed in a rearing isolator in Reference Laboratory for Quality Control on Poultry Production (RLQP), Dokki, Egypt (Biosafety Level 3 facilities). According to the manufacturer's recommended doses, three one-day-old chicks were vaccinated intranasally with the two preceding live attenuated vaccines. Tracheal swabs and organs (kidney, trachea and lung tissues) were collected from these birds five days post-vaccination. Tracheal and kidney tissues were individually homogenized in MEM with glucose. The supernatants were collected and regarded as the viral stocks of the initial passage. The viral stock of the first passage was inoculated in another three chicks and the method outlined for the first passage was repeated. This was deemed the second passage. This procedure was repeated until the tenth passage, with all viral stocks being tested for the presence of viral RNA and its quantity utilizing RT-qPCR targeting the N gene. All individual viral stocks were stored at −80 °C for subsequent S gene sequencing.

**Virus detection by real-time RT-PCR**

Extraction of viral RNA from the samples was done directly utilizing the Easy Pure viral RNA/DNA extraction kit (Trans - Cat No. ER201-01) in accordance with the manufacturer's instructions. The extracted viral RNAs were stored at -20°C till examination. The virus identification was made through Real-Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) for the existence of the N gene sequence of the IBV utilizing Verso one-step qRT-PCR kit plus ROX (Thermo Scientific, Cat No. AB-4100/A), via particular primers as well as probes that target the N gene (Meir et al., 2010).

**Sequencing of the S gene**

Subsequently, IBV-positive samples were examined using particular primer sets (Table 1) to amplify the S gene using Easyscript one-step RT-PCR kit (Trans - Cat No. AE411-02) according to the manufacturer’s protocol. Amplicons were excised and purified from gels using the QIAquick gel extraction kit- Cat No.28704 (Qiagen Inc. Valencia CA). The sequencing of the purified RT-PCR products was done using Bigdye Terminator V3.1 cycle sequencing kit (Perkin-Elmer, Foster City, CA) as well as a 3500 XL DNA Analyzer (Applied Biosystems). Genetic changes in isolates of both P6 and P10 were compared with IBV H120 vaccine published in the GenBank database with gene bank accession No. (FJ888351.1) and IB Var 2 vaccine sequenced in this study. BioEdit version 7.0 was used to read the output sequences and to create multiple sequence alignments (Hall, 2004).

**Table 1:** The sequence of primers of conventional RT-PCR for the identification of full spike gene.

| Nucleotide position | Forward primer sequence (5′-3′) | Reverse primer sequence (5′-3′) | Ref. |
|---------------------|---------------------------------|---------------------------------|------|
| 18,990–20,572       | AGTBTACYACACAGTTAYAAGCG        | GGYCTRWANKSRICTYTGTTAG         | (Abozeid et al., 2017) |
| 20,819–22,009        | TTAATCATTTACGTTGTTAAAT        | CATAACTAACATAAAGGGCAA          |      |
| 21,850–23,268        | GATGTCACACCAGCATTTGTA         | GCATACTGACTAGCATATTAGCTG       |      |

**3D Visualization of mutations in the S gene**

The majority of S1 protein's receptor binding domain and neutralizing epitopes were dispersed in the three HVRs frequently utilized for the classification of IBV genotypes as reported by previous studies (Moore et al., 1997; Wang and Huang, 2000). To establish a model structure for further investigation of mutations in the newly identified IBV strains as well as the HVRs, the S protein's 1140 aa of IB VAR2 vaccine was used. By comparing the S protein's deduced amino acid sequences of passages with those of the two vaccines, an alignment was established. Using the Swiss-Model repository's best-fit template (6cv0.1A) for a cryoelectron microscopy structure of the IBV spike protein, the 3D structure was constructed. The structure of the spike protein was retrieved and utilized as a model for the S monomer and trimer. The genetic changes of recovered viruses (P6 and P10) were detected and visualized using Geneious prime (Version 2020.1.2) (https://www.geneious.com/prime/).

**Prediction of N-linked glycosylation sites in IBV S protein**

N-glycosylation sites' gain or loss in the spike protein was predicted using the online server at http://www.cbs.dtu.dk/services/NetNGlyc

**RESULTS**

**Virus detection by Real Time RT-PCR**

Using RT-PCR assay, which targets the N gene, isolates of P6, P10 and used vaccines were detected positive for IBV.
Comparative amino acid analysis between currently used vaccines, P6 and P10 isolates

S gene of the IB VAR2 vaccine and reisolated viruses of P6 and P10 were sequenced for diversity analysis. The resulting amino acid sequences and nucleotides were aligned and matched to vaccinal strains. The characterized viruses of P6 and P10 in this study indicated that they shared nucleotide as well as amino acid sequence identities compared to the IB VAR2 vaccine currently in use, 98% and 96%, respectively. These isolates showed 55 nucleotide mutations, 23 substitutions were silent and 32 nucleotide mutations led to 26 changes in amino acid residues Table (2).

Table 2: Amino acid changes Spike protein in P6 and P10 compared to IB VAR2 and H120 vaccines.

| Serial | Position | H120 Vaccine | IB Variant II Vaccine | P6 and P10 |
|--------|----------|--------------|-----------------------|------------|
| 1      | 90       | A            | S                     | T          |
| 2      | 94       | S            | S                     | L          |
| 3      | 95       | Q            | E                     | Q          |
| 4      | 107      | T            | V                     | T          |
| 5      | 117      | G            | S                     | G          |
| 6      | 118      | G            | S                     | K          |
| 7      | 119      | -            | G                     | D          |
| 8      | 129      | Q            | Q                     | K          |
| 9      | 130      | H            | Y                     | N          |
| 10     | 131      | S            | Y                     | H          |
| 11     | 138      | K            | R                     | K          |
| 12     | 140      | G            | N                     | S          |
| 13     | 141      | Q            | S                     | Q          |
| 14     | 146      | L            | L                     | S          |
| 15     | 154      | P            | S                     | P          |
| 16     | 155      | T            | R                     | S          |
| 17     | 193      | A            | N                     | D          |
| 18     | 197      | I            | I                     | V          |
| 19     | 249      | S            | T                     | S          |
| 20     | 269      | T            | G                     | V          |
| 21     | 276      | H            | Y                     | H          |
| 22     | 320      | N            | N                     | D          |
| 23     | 387      | S            | T                     | A          |
| 24     | 392      | H            | O                     | R          |
| 25     | 439      | G            | G                     | S          |
| 26     | 451      | D            | D                     | A          |

Amino acid differences scattered throughout the mature S1 protein (aa19–532) as following: S90T, S94L, E95Q, V107T, S117G, S118K, G119D, Q129K, Y130N, Y131H, R138K, N140S, S141Q, L146S, S154P, R155S, N193D, I197V, T249S, G269V, Y276H, N320D, T387A, Q392R, G439S, D451A. HVRs in the S1 gene demonstrated unique patterns as well as substitutions of prominent amino acids, seven and one substitution, which were recorded in HVR2 and HVR3, respectively compared to the VAR2 vaccine. No mutations were observed in nucleotides or amino acids throughout the S2 gene (Fig. 1)

3D Visualization of Mutations

Significant amino acid changes were found in the primary receptor binding domain (aa 19–252) and close to HVR I and HVR II areas, as indicated by the 3D protein modeling in Fig. 2.

Fig.2: The 3D structure was modeled using the Swiss-Model repository's best-fit template (6cv0.1.A) of a cryoelectron microscopy structure of the IBV spike protein. The 3D structure was visualized by Geneious prime. HVR I is cyan, HVR II is purple and HVR III is blue. The 3D structure on the left is a spike monomer showing the mutation on one chain and that on the right is a spike trimer.
Prediction of N-linked glycosylation sites in IBV S protein

The analysis predicts several glycosylation sites in S1 protein. Passages 6 and 10 had 17 glycosylation sites and lacked an IBV glycosylation site at position 139 which was observed in IBV/EG/1212B/2012 and IB VAR2 vaccine and glycosylation site at position 284 compared to H120. H120 had 18 glycosylation sites and lacked IBV glycosylation site at position 139. The predicted glycosylation sites in S1 protein of IB VAR2 vaccine are 18 and lacked glycosylation site at position 284 compared to H120 Table (3).

Table 3: Glycosylation sites predicted in S1 using NetNGlyc-1.0 in H120, IB VAR2 vaccine and both passages.

| Serial | H120 | IB VAR2 Vaccine | Isolates of P6 and P10 |
|--------|------|----------------|-----------------------|
| 1      | 51   | 51             | 51                    |
| 2      | 77   | 74             | 74                    |
| 3      | 103  | 102            | 102                   |
| 4      | -    | 139            | -                     |
| 5      | 145  | 145            | 145                   |
| 6      | 164  | 164            | 164                   |
| 7      | 179  | 179            | 179                   |
| 8      | 213  | 213            | 213                   |
| 9      | 238  | 238            | 238                   |
| 10     | 248  | 248            | 248                   |
| 11     | 265  | 265            | 265                   |
| 12     | 272  | 272            | 272                   |
| 13     | 277  | 277            | 277                   |
| 14     | 284  | -              | -                     |
| 15     | 307  | 307            | 307                   |
| 16     | 426  | 426            | 426                   |
| 17     | 448  | 448            | 448                   |
| 18     | 514  | 514            | 514                   |
| 19     | 531  | 531            | 531                   |

DISCUSSION

Vaccination is the most efficient method for decreasing IBV-related economic losses. However, decreased cross-protection, as well as maximum antigenic variability between the circulating genotypes, require the use of various vaccine combinations to expand the protection spectrum (Li et al., 1994; Hussein et al., 2014). In the field, live attenuated vaccines have effectively controlled IB (Cook et al., 1999; De Wit et al., 2011). They are characterized by ease of application and high protection against disease (Cook et al., 2012). Utilizing live attenuated vaccines carries the risk of vaccine breakdown or reversal to virulence (Hopkins and Yoder, 1986; Thor et al., 2011). Using different serotypes/variants provide low or no cross-protection against each other (Cavanagh, 2007). Vaccines that do not provide adequate protection due to serotype differences can increase the shedding level and the emergence of viral escape mutants (Arinaminpathy et al., 2012; Lin and Chen, 2017).

This study established an in-vivo infection model to identify genetic variation within the S gene after 10 passages of two live attenuated IBV vaccines H120 and IB VAR2, co-inoculated in the same chicken. P6 and P10 in this study were identified as the IB VAR2 vaccine with amino acid identity (96%) suggesting an early and dramatic predominance of the IB VAR2 vaccine over the replication of H120 vaccine within the same chicken. Regarding the two IBV vaccine serotypes, Ball et al., 2017 revealed that the maximized 793B strains’ ability to replicate at a higher rate over the Mass strains within the same host and that the Mass1 strain replicated faster than the D274 strain (Ball et al., 2017).

Viruses P6 and P10 demonstrated 55 single nucleotide polymorphisms (SNPs), 23 SNPs were synonymous and 32 SNPs were nonsynonymous (led to 26 changes of amino acid residues) compared to IB VAR2 vaccine. These genetic changes identified in S1 of both passages suggest that competition for replication of the two vaccines may have impacted the genetic variability in the sequenced strain of IB VAR2 vaccine. However, further study is needed to prove this hypothesis by investigating the genetic alterations of recovered isolates over 10 passages from a group vaccinated with VAR2 vaccine only. Ball et al., (2016) reported that the individual 793B vaccine appeared to have greater stability.

However, in the presence of Mass, there was a marked increase in 793B SNPs per 100 bp, with the majority now causing a change in the amino acid composition. Live IBV vaccine viruses, administered separately or in combination with day-old commercial broiler chicks, revealed that most SNPs found within the recovered IBV vaccine strain resulted in amino acid alterations (Ball et al., 2017). The S1 protein contained HVRs linked to virus-neutralizing epitopes and serotype specificity and located within the amino acid residues 38–67, 91–141, and 274–387 (Moore et al., 1997; Wang and Huang 2000).

The prominent amino acid substitutions within HVR II and III compared to the IB VAR2 vaccine were as follows in HVR2, the mutations were S117G, S118K, G119D, Q1129K, Y130N, Y131H, R138K, N140S, S141Q and in HVR3 was only a single mutation Y276H. It is evident that even a minor alteration in the amino acid sequence of the spike protein may contribute to generating new serotypes, or genotypes, which are antigenically different from the current classic as well as variant vaccine strains.
Both passages (6th and 10th) have different amino acids compared to the IB VAR2 vaccine. Asparagine and glutamine within this region at positions 131 and 142 (130-141 in H120) instead of Tyrosine and Serine in the IB VAR2 vaccine and Histidine and Glutamine in H120, respectively. The same positions have changes in Egypt/F/03 strain that are closely related to the Mass serotype and they have been suggested to be responsible for pathogenicity alteration, elucidating the high virulence of Egypt/F/03 and the inability of H120 to provide satisfactory protection against challenges (Abdel-Moneim et al., 2006; Abozeid and Naguib, 2020).

P6 and P10 have four prominent amino acid substitutions approximate to the HVR I/II (S90T, S94L, E95Q and V107T) that could contribute to the change of virus antigenicity and facilitate the emergence of variant strains primarily because of localization of these mutations within the RBD. In the current study, the obtained results align with the findings of Rohaim et al., (2020) who localized three amino acid substitutions in the spike protein of IBV strains compared to their parental origin at positions 94, 95 and 105 within the RBD. Passages 6 and 10 lacked IBV glycosylation site at position 139 which was detected in IBV/EG/1212B/2012 and IB VAR2 strain compared to H120 which also lacked this glycosylation site. This finding may affect spike protein modification and folding, viral receptor binding, or virus-cell and cell-cell fusion.

CONCLUSION

Heterologous vaccination in the same chicken may be a factor in S1 genetic variability that may result in escape mutants. A further study is needed to prove this speculation by investigating the genetic changes resulting from passaging of IB VAR2 vaccine individually ten times in SPF chicks to know whether the competition between both vaccines is the main cause of variability. Also, it is needed to work hard on combinations of vaccines and their impact on the evolution of IBV.

Conflict of interest

The authors declare that they are not involved in any potential conflicts of interest.

REFERENCES

Abdel-Moneim, A.S., El-Kady, M.F., Ladman, B.S., and Gelb, J., 2006. S1 gene sequence analysis of a neuropathogenic strain of avian infectious bronchitis virus in Egypt. Virology journal, 3(1), 1-9. DOI: 10.1186/1743-422X-3-78

Abdel-Sabour, M.A., Al-Ebsahay, E.M., Khalieal, S.A., Abdel-Wanis, N.A., and Yanai, T., 2017. Isolation and molecular characterization of novel infectious bronchitis virus variants from vaccinated broiler flocks in Egypt. Avian diseases, 61(3), 307-310. https://DOI.org/10.1637/11566-121516-RegR

Abozied, H.H., and Naguib, M.M., 2020. Infectious bronchitis virus in Egypt: Genetic diversity and vaccination strategies. Veterinary Sciences, 7(4), 204. https://DOI.org/10.3390/vetsci7040204

Abozied, H.H., PalDurai, A., Khattar, S.K., Afifi, M.A., El-Kady, M.F., El-Deeb, A.H., and Samal, S.K., 2017. Complete genome sequences of two avian infectious bronchitis viruses isolated in Egypt: evidence for genetic drift and genetic recombination in the circulating viruses. Infection, Genetics and Evolution, 53, 7-14. https://DOI.org/10.1016/j.meegid.2017.05.006

Adzhar, A., Gough, RE, Haydon, D., Shaw, K., Britton, P., and Cavanagh, D., 1997. Molecular analysis of the 793/B serotype of infectious bronchitis virus in Great Britain. Avian Pathology, 26(3), 625-640. https://DOI.org/10.1080/03079459708419239

Ali, A., Kilany, W.H., El-Abdeen, M.A.Z., El-Sayed, M. and El-Kady, M., 2018. Safety and efficacy of attenuated classic and variant 2 infectious bronchitis virus candidate vaccines. Poultry Science, 97(12), 4238-4244. https://DOI.org/10.3382/ps/pys312

Arinaminpathy, N., Ratmann, O., Koelle, K., Epstein, SL, Price, GE, Viboud, C., Miller, M.A., and Grenfell, BT, 2012. Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proceedings of the National Academy of Sciences, 109(8), 3173-3177. https://DOI.org/10.1073/pnas.1113342109

Ball, C., Bennett, S., Forrester, A., and Ganapathy, K., 2016. Genetic mutations in live infectious bronchitis vaccine viruses following single or dual in vitro infection of tracheal organ cultures. Journal of General Virology, 97, 3232-3237. DOI: 10.1099/jgv.0.000628

Ball, C., Awad, F., Hutton, S., Forrester, A., Baylis, M., and Ganapathy, K., 2017. Infectious bronchitis vaccine virus detection and part-S1 genetic variation following single or dual inoculation in broiler chicks. Avian Pathology, 46(3), 309-318. https://DOI.org/10.1080/03079457.2016.1268675

Belouzard, S., Millet, JK, Licittra, B.N., and Whittaker, GR, 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses, 4(6), 1011-1033. https://DOI.org/10.3390/v4061011

Bijlenga, G., Cook, J.K., Gelb, JR, and Wit, J.D., 2004. Development and use of the H strain of...
avian infectious bronchitis virus from the Netherlands as a vaccine: a review. Avian Pathology, 33(6), 550-557. https://DOI.org/10.1080/0307945040013154.

BINNS, M.M., BOURSNEILL, M.E., TOMLEY, F.M., and BROWN, T.D.K., 1986. Comparison of the spike precursor sequences of coronavirus IBV strains M41 and 6/82 with that of IBV Beaudette. Journal of General Virology, 67(12), 2825-2831. https://DOI.org/10.1099/0022-1317-67-12-2825.

BOSCH, B.J., VAN DER ZEE, R., DE HAAN, C.A., and ROTTIER, P.J., 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. Journal of virology, 77(16), 8801-8811. https://DOI.org/10.1128/JVI.77.16.8801-8811.2003.

CAVANAGH, D. 1995. The Coronavirus Surface Glycoprotein. In: Siddell, S.G. (eds) The Coronaviridae. The Viruses. Springer, Boston, MA, 73-113. https://DOI.org/10.1007/978-1-4899-1531-3_5.

CAVANAGH, D. 2007. Coronavirus avian infectious bronchitis virus. Veterinary Research, 38(2), 281-297. DOI: 10.1051/vetres:2006055.

CAVANAGH, D., DAVIS, P.J., and MOCKETT, A.A., 1988. Amino acids within hypervariable region 1 of avian coronavirus IBV (Massachusetts serotype) spike glycoprotein are associated with neutralization epitopes. Virus Research, 11(2), 141-150. https://DOI.org/10.1016/0168-1702(88)90039-1.

CAVANAGH, D., DAVIS, P.J., COOK, J.K., LI, D., KANT, A., and KOCH, G., 1992. Location of the amino acid differences in the S1 spike glycoprotein subunit of closely related serotypes of infectious bronchitis virus. Avian Pathology, 21(1), 33-43. https://DOI.org/10.1080/03079459208418816.

COOK, J.K., ORBELL, S.J., WOODS, M.A., and HUGGINS, M.B., 1999. Breadth of protection of the respiratory tract provided by different live-attenuated infectious bronchitis vaccines against challenge with infectious bronchitis viruses of heterologous serotypes. Avian Pathology, 28(5), 477-485. https://DOI.org/10.1080/0307945994506.

COOK, J.K., JACKWOOD, M., and JONES, R.C., 2012. The long view: 40 years of infectious bronchitis research. Avian Pathology, 41(3), 239-250. https://DOI.org/10.1080/03079457.2012.680432.

DE WIT, J.J., NIEUWENHUISEN-VAN WILGEN, J., HOOGKAMER, A., VAN DE SANDE, H., ZUIDAM, G.J., and FABRI, T.I.F., 2011. Induction of cystic oviducts and protection against early challenge with infectious bronchitis virus serotype D388 (genotype QX) by maternally derived antibodies and by early vaccination. Avian Pathology, 40(5), 463-471. https://DOI.org/10.1080/03079457.2011.599060.

GANAPATHY, K. 2009. Diagnosis of infectious bronchitis in chickens. In Practice, 31(9), 424-431. https://DOI.org/10.1136/impract.31.9.424.

GHETAS, A.M., KUTKAT, M.A., AMER, M.M., and AWAAD, M.H., 2016. Isolation and molecular identification of IBV isolates in different governorates in Egypt. Journal of the Egyptian Society of Parasitology, 46(2), 341-346. DOI: 10.21608/jesp.2016.88682.

HALL, T. 2004. BioEdit version 7.0.0. Distributed by author. http://www.mbio.ncsu.edu/BioEdit/bioedit.html.

HAN, DP, LOHANI, M. and CHO, MW, 2007. Specific asparagine-linked glycosylation sites are critical for DC-SIGN-and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. Journal of Virology, 81(21), 12029-12039. https://DOI.org/10.1128/JVI.00315-07.

HEWSON, K.A., NOORMOHAMMADI, A.H., DEVLIN, J.M., BROWNING, G.F., SCHULTZ, B.K., and IGNIJATOVIC, J., 2014. Evaluation of a novel strain of infectious bronchitis virus emerged as a result of spike gene recombination between two highly diverged parent strains. Avian Pathology, 43(3), 249-257. https://DOI.org/10.1080/03079457.2014.914624.

HOPKINS, S.R., and YODER J.R. H.W., 1986. Reversion to virulence of chicken-passaged infectious bronchitis vaccine virus. Avian Diseases, 30(1), 221-223. https://DOI.org/10.2307/1590639.

HUSSEIN, A.H., EMARA, M.M., ROHAIM, M.A., GANAPATHY, K., and ARAFA, A.M., 2014. Sequence analysis of infectious bronchitis virus IS/1494 like strain isolated from broiler chicken co-infected with Newcastle disease virus in Egypt during 2012. International Journal of Poultry Science 13(9), 530-536. DOI: 10.3922/jips.2014.530.536.

JACKWOOD, M.W. 2012. Review of infectious bronchitis virus around the world. Avian Diseases, 56(4), 634-641. https://DOI.org/10.1637/10227-043012-Review.1.

JACKWOOD, M.W., and DE WIT, S., 2013. Infectious bronchitis. Diseases of Poultry,14th edition. 139-159. https://DOI.org/10.1007/9781119371199.ch4.

KANT, A., KOCH, G., VAN ROOZELAAR, D.J., KUSTERS, J.G., POELWIJK, F.A.J., and VAN DER ZEIJSJT, B.A.M., 1992. Location of antigenic sites defined by neutralizing monoclonal antibodies on the S1 avian infectious bronchitis virus glycopolypeptide. Journal of General Virology, 73(3), 591-596. https://DOI.org/10.1099/0022-1317-73-3-591.

KOCH, G., HARTOG, L., KANT, A.V., and VAN ROOZELAAR, D.J., 1990. Antigenic domains on the peplomer protein of avian infectious bronchitis virus: correlation with biological functions. Journal of General Virology, 71(9), 1929-1935. https://DOI.org/10.1099/0022-1317-71-9-1929.

KUSTERS, J.G., NIESTERS, H.G.M., LENSTRA, J.A., HORZINEK, M.C., and VAN DER ZEIJT, B.A.M., 1989. Phylogeny of antigenic variants of avian coronavirus IBV. Virology, 169(1), 217-221. https://DOI.org/10.1016/0042-6822(89)90058-5.

LI, W., JUNKER, D., HOCK, L., EIBIARY, E., and COLLIS, EW, 1994. Evolutionary implications of genetic variations in the S1 gene of infectious bronchitis virus. Virus Research, 34(3), 327-338. https://DOI.org/10.1016/0168-1702(94)90132-5.

LIN, S.Y., and CHEN, H.W., 2017. Infectious bronchitis virus variants: molecular analysis and pathogenicity investigation. International Journal of Molecular Sciences, 18(10), 2030. https://DOI.org/10.3390/ijms18102030.

MASTERS, P.S., and PERLMAN, S., 2013. Coronaviridae. In Fields Virology, (Kneipe, DM and Howley, PM, eds) 2, 825–858.
Emerging infectious bronchitis virus, UR, Genotyping and pathotyping of. Monoclonal antibodies to the S1 spike. Development of a real–infectious bronchitis virus. Relationship Structural basis for human coronavirus, 2017. MOORE, K., MOCKETT, A,A. BEER, M., MUNIR, M., 2020. delta coronavirus spike protein in the prefusion 8.50023 Ltd. Immunology https://DOI.org/10.978-32-00023. MOCHI, K., JACKWOOD, M., and HILT, D.A. 1997. Identification of amino acids involved in a serotype and neutralization specific epitope within the s1 subunit of avian infectious bronchitis virus. Archives of Virology, 142(11), 2249-2256. DOI: 10.1007/s007050050239 PAYNE, S. 2017. Chapter 17-Family Coronaviridae”. In Viruses, editie de Susan Payne, 149–58. DOI: 10.1016/B978-0-12-803109-4.00017-9. ROHAIM, MA, EL NAGGAR, RF, ABIDEEN, M.A. and BROWN, M., 2010. Binding of avian coronavirus spike proteins to host factors reflects virus tropism and pathogenicity. Journal of Virology, 85(17), 8903-8912. Figure DOI: 10.1128/JVI.05112-11 ZANATY, A., ARAFA, A.S., HAGAG, N., and EL-KADY, M., 2016B. Genotyping and pathotyping of diversified strains of infectious bronchitis viruses circulating in Egypt. World Journal of Virology, 5(3), 125. doi: 10.5501/wjv.s.vi.s.125. ZHENG, J., YAMADA, Y., FUNG, T.S., HUANG, M., CHIA, R., and LIU, D.X., 2018. Identification of N-linked glycosylation sites in the spike protein and their functional impact on the replication and infectivity of coronavirus infectious bronchitis virus in cell culture. Virology, 513, 65-74. DOI: 10.1016/j.virol.2017.10.003 ZHOU, Y., LU, K., PFEFFERLE, S., BERTRAM, S., GLOWACKA, I., DROSTEN, C., PÖHLMANN, S., and SIMMONS, G., 2010. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. Journal of virology, 84(17), 8753-8764. DOI: 10.1128/JVI.00554-10 How to cite this article: Sara M. Ameen, Abdullah Selim, Mohamed Tarek, Ali Zanaty, Mohammed AboElKhair and AbdelHamid H. Bazid. 2023. Genetic Changes of S Gene during Co-inoculation of Two Infectious Bronchitis Virus Vaccines in SPF Chicks. Journal of Applied Veterinary Sciences, 8 (1): 18–25. DOI: https://dx.doi.org/10.21608/javs.2022.159573.1177